The history of the agnostic targeting of neoplastic growth originates from attempts to utilize tamoxifen, a well-known breast cancer drug directed against the estrogen receptor (ER), for the treatment of ER+ pulmonary lymphangiomyomatosis [6]. The gene discussed is ESR1; the disease is breast carcinoma.